Globus Medical Inc Quick Ratio (GMED) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Globus Medical Inc   (NYSE: GMED)

Globus Medical Inc 's Quick Ratio

GMED's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the second quarter 2026, Quick Ratio deteriorated to 1.24 below Globus Medical Inc 's average Quick Ratio.

Within Medical Equipment & Supplies industry 103 other companies have achieved higher Quick Ratio than Globus Medical Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 992 to 1635.

Explain Quick Ratio?
How much Cash & cash equivalents GMED´s has?
What are GMED´s Current Liabilities?




GMED Quick Ratio (Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
(Jun 30 2025)
Q2
Y / Y Current Liabilities Change 228.46 % 25.41 % -38.34 % -43.04 % -81.62 %
Y / Y Cash & cash equivalent Change - - 427.6 % -73.93 % -
Quick Ratio MRQ 1.24 1.31 1.06 0.04 -
GMED's Total Ranking # 1635 # 992 # 1254 # 2895 # 0
Seq. Current Liabilities Change -0.65 % -8.58 % 13.26 % 219.28 % -62.06 %
Seq. Cash & cash equivalent Change -5.51 % 13.03 % 2871.33 % - -



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 104
Healthcare Sector # 594
Overall Market # 1635


Quick Ratio Statistics
High Average Low
5.73 2.64 0.04
(Sep 30 2012)   (Sep 30 2025)




Financial Statements
Globus Medical Inc 's Current Liabilities $ 479 Millions Visit GMED's Balance sheet
Globus Medical Inc 's Cash & cash equivalent $ 595 Millions Visit GMED's Balance sheet
Source of GMED's Sales Visit GMED's Sales by Geography


Cumulative Globus Medical Inc 's Quick Ratio

GMED's Quick Ratio for the trailling 12 Months

GMED Quick Ratio

(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
(Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -11.3 % -43.14 % -53.16 % -34.33 % -9.33 %
Y / Y Cash & cash equivalent TTM Growth 914.31 % 363.67 % 69.17 % -56.41 % -55.91 %
Quick Ratio TTM 0.92 0.74 0.38 0.07 0.08
Total Ranking TTM # 4025 # 3000 # 2518 # 3097 # 3013
Seq. Current Liabilities TTM Growth 20.55 % 6.41 % -17.72 % -15.97 % -22.72 %
Seq. Cash & cash equivalent TTM Growth 49.35 % 109.35 % 363.12 % -29.95 % -31.73 %


On the trailing twelve months basis GMED Cash & cash equivalent decreased by -5.51 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Globus Medical Inc 's Quick Ratio to 0.92, Quick Ratio remained below GMED average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Equipment & Supplies industry 201 other companies have achieved higher Quick Ratio than Globus Medical Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3000 to 4025.

Explain Quick Ratio?
How much Cash & cash equivalents GMED´s has?
What are GMED´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Medical Equipment & Supplies Industry # 202
Healthcare Sector # 901
Within the Market # 4025


trailing twelve months Quick Ratio Statistics
High Average Low
5.43 2.46 0.06
(Dec 31 2012)   (Sep 30 2025)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Medical Equipment & Supplies Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Outset Medical Inc   3.35 $ 147.194  Millions$ 43.891  Millions
Inspiremd Inc   3.15 $ 30.421  Millions$ 9.646  Millions
Fractyl Health Inc   3.00 $ 47.140  Millions$ 15.736  Millions
Vivani Medical Inc   2.99 $ 19.894  Millions$ 6.659  Millions
Retractable Technologies Inc  2.98 $ 39.870  Millions$ 13.365  Millions
Neuropace Inc   2.97 $ 51.700  Millions$ 17.433  Millions
Apyx Medical Corp  2.95 $ 27.617  Millions$ 9.354  Millions
Omada Health Inc   2.94 $ 221.712  Millions$ 75.483  Millions
Clearpoint Neuro Inc   2.85 $ 29.363  Millions$ 10.313  Millions
Penumbra Inc  2.82 $ 658.795  Millions$ 233.776  Millions
Glaukos Corp  2.80 $ 286.594  Millions$ 102.329  Millions
Pulmonx Corporation  2.76 $ 56.393  Millions$ 20.405  Millions
Intuitive Surgical Inc   2.71 $ 5,216.200  Millions$ 1,922.900  Millions
Neuraxis Inc   2.69 $ 8.342  Millions$ 3.096  Millions
Edwards Lifesciences Corporation  2.68 $ 4,291.700  Millions$ 1,604.100  Millions
Modular Medical Inc  2.63 $ 3.920  Millions$ 1.489  Millions
Co diagnostics Inc   2.55 $ 7.299  Millions$ 2.863  Millions
Staar Surgical Co  2.47 $ 181.489  Millions$ 73.394  Millions
Electromed Inc   2.35 $ 20.450  Millions$ 8.714  Millions
EBR Systems, Inc.  2.18 $ 113.533  Millions$ 52.023  Millions
Medinotec Inc   2.15 $ 2.519  Millions$ 1.171  Millions
Atricure Inc   2.05 $ 167.786  Millions$ 81.916  Millions
Tactile Systems Technology Inc   1.83 $ 69.853  Millions$ 38.253  Millions
Tandem Diabetes Care Inc   1.80 $ 455.996  Millions$ 253.005  Millions
Inspire Medical Systems inc   1.79 $ 127.761  Millions$ 71.282  Millions
Warby Parker Inc   1.79 $ 292.674  Millions$ 163.480  Millions
Capsovision Inc   1.76 $ 9.077  Millions$ 5.158  Millions
Anika Therapeutics Inc   1.73 $ 38.412  Millions$ 22.147  Millions
Genedx Holdings Corp   1.71 $ 132.548  Millions$ 77.648  Millions
Beta Bionics Inc   1.70 $ 44.318  Millions$ 26.017  Millions

Date modified: 2026-09-08T17:55:39+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.